The Global Initiative for Asthma (GINA) has developed a comprehensive strategy for asthma management and prevention, emphasizing the importance of achieving and maintaining asthma control. The 2006 GINA report highlights that asthma control should be the focus of treatment decisions, rather than asthma severity. It recommends a patient-care giver partnership, guided self-management, and setting treatment goals. The report also outlines five components of asthma management: developing a patient-care giver partnership, identifying and reducing exposure to risk factors, assessing, treating, and monitoring asthma, managing asthma exacerbations, and considering special circumstances. The report discusses the burden of asthma, noting that it affects an estimated 300 million people worldwide. Asthma prevalence varies by country, with increasing trends in some regions and stabilization or decline in others. The economic and social impact of asthma is significant, with asthma-related deaths estimated at 250,000 annually. The report emphasizes the need for asthma care to be adapted to local conditions and resources. The report outlines the classification of asthma based on control levels, with recommendations for treatment steps. It emphasizes the importance of inhaled glucocorticosteroids as a primary controller medication, along with other options such as leukotriene modifiers, long-acting inhaled β₂-agonists, and anti-IgE therapy. The report also discusses the use of reliever medications, including rapid-acting inhaled β₂-agonists, anticholinergics, and short-acting oral β₂-agonists. For children, the report emphasizes the importance of inhaled therapy, with specific recommendations for inhaler devices and dosing. It also discusses the use of controller medications, including inhaled and systemic glucocorticosteroids, leukotriene modifiers, long-acting inhaled β₂-agonists, theophylline, and cromones. The report highlights the importance of proper dosing, monitoring, and adjusting treatment to achieve and maintain asthma control. It also discusses the potential side effects of asthma medications and the importance of careful dose selection and monitoring.The Global Initiative for Asthma (GINA) has developed a comprehensive strategy for asthma management and prevention, emphasizing the importance of achieving and maintaining asthma control. The 2006 GINA report highlights that asthma control should be the focus of treatment decisions, rather than asthma severity. It recommends a patient-care giver partnership, guided self-management, and setting treatment goals. The report also outlines five components of asthma management: developing a patient-care giver partnership, identifying and reducing exposure to risk factors, assessing, treating, and monitoring asthma, managing asthma exacerbations, and considering special circumstances. The report discusses the burden of asthma, noting that it affects an estimated 300 million people worldwide. Asthma prevalence varies by country, with increasing trends in some regions and stabilization or decline in others. The economic and social impact of asthma is significant, with asthma-related deaths estimated at 250,000 annually. The report emphasizes the need for asthma care to be adapted to local conditions and resources. The report outlines the classification of asthma based on control levels, with recommendations for treatment steps. It emphasizes the importance of inhaled glucocorticosteroids as a primary controller medication, along with other options such as leukotriene modifiers, long-acting inhaled β₂-agonists, and anti-IgE therapy. The report also discusses the use of reliever medications, including rapid-acting inhaled β₂-agonists, anticholinergics, and short-acting oral β₂-agonists. For children, the report emphasizes the importance of inhaled therapy, with specific recommendations for inhaler devices and dosing. It also discusses the use of controller medications, including inhaled and systemic glucocorticosteroids, leukotriene modifiers, long-acting inhaled β₂-agonists, theophylline, and cromones. The report highlights the importance of proper dosing, monitoring, and adjusting treatment to achieve and maintain asthma control. It also discusses the potential side effects of asthma medications and the importance of careful dose selection and monitoring.